Seastar Medical Holding CORP 8-K Filing
Ticker: ICUCW · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1831868
| Field | Detail |
|---|---|
| Company | Seastar Medical Holding CORP (ICUCW) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Seastar Medical Holding CORP (ticker: ICUCW) to the SEC on Dec 18, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common Stock par value $0.0001 per share ICU The Nasdaq Stock Marke); $11.50 (sable for one share of Common Stock for $11.50 per share ICUCW The Nasdaq Stock Ma).
How long is this filing?
Seastar Medical Holding CORP's 8-K filing is 3 pages with approximately 904 words. Estimated reading time is 4 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 904 words · 4 min read · ~3 pages · Grade level 13.3 · Accepted 2025-12-18 16:22:38
Key Financial Figures
- $0.0001 — ich registered Common Stock par value $0.0001 per share ICU The Nasdaq Stock Marke
- $11.50 — sable for one share of Common Stock for $11.50 per share ICUCW The Nasdaq Stock Ma
Filing Documents
- icu20251217_8k.htm (8-K) — 36KB
- 0001437749-25-038276.txt ( ) — 185KB
- icu-20251218.xsd (EX-101.SCH) — 4KB
- icu-20251218_def.xml (EX-101.DEF) — 14KB
- icu-20251218_lab.xml (EX-101.LAB) — 18KB
- icu-20251218_pre.xml (EX-101.PRE) — 14KB
- icu20251217_8k_htm.xml (XML) — 5KB
03 - Material Modification to Rights of Security Holders
Item 3.03 - Material Modification to Rights of Security Holders On December 18, 2025, SeaStar Medical Holding Corporation ("the Company") held a special meeting of the shareholders (the "Special Meeting") during which the stockholders approved a 1-for-10 reverse stock split of the Company's common stock (the "Reverse Split"). The Board of Directors of the Company previously approved the Reverse Split subject to stockholder approval. The Reverse Split will be effective as of 12:01 AM Eastern Standard Time on January 2, 2026, and the Company's shares of common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on January 2, 2026 under the same symbol "ICU". All stock options and warrants of the Company outstanding immediately prior to the Reverse Split will be proportionally adjusted. As a result of the Reverse Split, every 10 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.0001 per share. The Company will not issue any fractional shares in connection with the Reverse Split. Instead, the number of shares will be rounded up to the next whole number. The Reverse Split will not modify the rights or preferences of the common stock. Immediately after the Reverse Split becomes effective, there will be approximately 3.8 million shares of common stock issued and outstanding. The Company has appointed its transfer agent, Continental Stock Transfer and Trust Company, Inc., to act as exchange agent for the reverse stock split. Stockholders owning shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the Reverse Split and will not be required to take further action in connection with the Reverse Split, subject to brokers' particular processes.
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The Special Meeting was held virtually on December 18, 2025 at 10:00 a.m., Mountain Time. The following proposals were approved by the stockholders, each by the votes set forth below: Proposal 1 . To approve an Amendment to our Third Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation") to effect a reverse stock split of the Company's Common Stock at a ratio of 1-for-10, without reducing the authorized number of shares of the Common Stock, to be effected in the sole discretion of the Board at any time within one year of the date of the Special Meeting without further approval or authorization of stockholders (the "Reverse Stock Split Proposal") Votes For Votes Against Abstentions Broker Non-Votes 16,454,058 5,600,251 124,514 — Proposal 2 . To approve an Amendment to our Certificate of Incorporation to reduce the number of authorized shares of common stock by 25,000,000 to 425,000,000 (the "Authorized Share Proposal") Votes For Votes Against Abstentions Broker Non-Votes 18,617,183 3,465,583 96,057 — Proposal 3 . To approve a proposal to adjourn or postpone the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal or Authorized Share Proposal Votes For Votes Against Abstentions Broker Non-Votes 17,092,841 4,844,571 241,411 —
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SeaStar Medical Holding Corporation By: /s/ Eric Schlorff Date: December 18, 2025 Name: Eric Schlorff Title: Chief Executive Officer